Journal ArticleDOI
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer : National surgical adjuvant breast and bowel project protocol B-27
Harry Douglas Bear,Stewart J. Anderson,Roy E. Smith,Charles E. Geyer,Eleftherios P. Mamounas,Bernard Fisher,Ann M. Brown,André Robidoux,Richard G. Margolese,Morton S. Kahlenberg,Soonmyung Paik,Atilla Soran,D. Lawrence Wickerham,Norman Wolmark +13 more
TLDR
The addition of preoperative or postoperative T after preoperative AC did not significantly affect OS, slightly improved DFS, and decreased the incidence of local recurrences.Abstract:
Purpose This study was designed to determine the effect of adding docetaxel (T) to preoperative doxorubicin and cyclophosphamide (AC) on breast cancer response rates and disease-free survival (DFS) and overall survival (OS). Patients and Methods Women with operable breast cancer (N = 2,411) were randomly assigned to receive preoperative AC followed by surgery, AC followed by T and surgery, or AC followed by surgery and then T. Tamoxifen was initiated concurrently with chemotherapy. Median time on study for 2,404 patients with follow-up was 77.9 months. Results Addition of T to AC did not significantly impact DFS or OS. There were trends toward improved DFS with addition of T. The addition of T reduced the incidence of local recurrences as first events (P = .0034). Preoperative T, but not postoperative T, significantly improved DFS in patients who had a clinical partial response after AC (hazard ratio [HR] = 0.71; 95% CI, 0.55 to 0.91; P = .007). Pathologic complete response, which was doubled by addition ...read more
Citations
More filters
Journal ArticleDOI
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz,Michael Untch,Jens-Uwe Blohmer,SD Costa,Holger Eidtmann,Peter A. Fasching,Bernd Gerber,Wolfgang Eiermann,Jörn Hilfrich,Jens Huober,Christian Jackisch,Manfred Kaufmann,Gottfried E. Konecny,Carsten Denkert,Valentina Nekljudova,Keyur Mehta,Sibylle Loibl +16 more
TL;DR: The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain this paper, however, it is known that pCR is associated with long-term outcome of 6,377 patients with primary breast cancer receiving neoadjuvant anthracycline-taxane-based chemotherapy in seven randomized trials.
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi,Stewart J. Anderson,Harry D. Bear,Charles E. Geyer,Morton S. Kahlenberg,André Robidoux,Richard G. Margolese,James L. Hoehn,Victor G. Vogel,Shaker R. Dakhil,Deimante Tamkus,Karen M. King,Eduardo R. Pajon,Mary Johanna Wright,Jean Robert,Soonmyung Paik,Eleftherios P. Mamounas,Norman Wolmark +17 more
TL;DR: B-18 and B-27 demonstrate that preoperative therapy is equivalent to adjuvant therapy and showed that the addition of preoperative taxanes to AC improves response.
Journal ArticleDOI
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
W. Fraser Symmans,Florentia Peintinger,Christos Hatzis,Radhika Rajan,Henry Mark Kuerer,Vicente Valero,Lina Assad,Anna Poniecka,Bryan T. Hennessy,Marjorie C. Green,Aman U. Buzdar,S. Eva Singletary,Gabriel N. Hortobagyi,Lajos Pusztai +13 more
TL;DR: Residual cancer burden was calculated as a continuous index combining pathologic measurements of primary tumor and nodal metastases and was a significant predictor of distant relapse-free survival (DRFS) in multivariate Cox regression analyses.
Journal ArticleDOI
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Norikazu Masuda,Soo Jung Lee,Shoichiro Ohtani,Young-Hyuck Im,Eun Sook Lee,Isao Yokota,Katsumasa Kuroi,Seock-Ah Im,Byeong Woo Park,Sung-Bae Kim,Yasuhiro Yanagita,Shinji Ohno,Shintaro Takao,Kenjiro Aogi,Hiroji Iwata,Joon Jeong,Ae-Ree Kim,K. H. Park,Hironobu Sasano,Yasuo Ohashi,Masakazu Toi +20 more
TL;DR: After standard neoadjuvant chemotherapy containing anthracycline, taxane, or both, the addition of adjuvant capecitabine therapy was safe and effective in prolonging disease‐free survival and overall survival among patients with HER2‐negative breast cancer who had residual invasive disease on pathological testing.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal ArticleDOI
The Statistical Analysis of Failure Time Data.
Journal ArticleDOI
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
TL;DR: In this paper, a class of tests developed for comparing the cumulative incidence of a particular type of failure among different groups is presented. The tests are based on comparing weighted averages of the hazards of the subdistribution for the failure type of interest.
Journal ArticleDOI
Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy
Marie Overgaard,Per S. Hansen,Jens Overgaard,Carsten Rose,Martin Andersson,Flemming W. Bach,Mogens Kjaer,Carl C. Gadeberg,Henning T. Mouridsen,Maj-Britt Jensen,Karin Zedeler +10 more
TL;DR: Multivariate analysis demonstrated that irradiation after mastectomy significantly improved disease-free survival and overall survival, irrespective of tumor size, the number of positive nodes, or the histopathological grade.
Related Papers (5)
Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi,Stewart J. Anderson,Harry D. Bear,Charles E. Geyer,Morton S. Kahlenberg,André Robidoux,Richard G. Margolese,James L. Hoehn,Victor G. Vogel,Shaker R. Dakhil,Deimante Tamkus,Karen M. King,Eduardo R. Pajon,Mary Johanna Wright,Jean Robert,Soonmyung Paik,Eleftherios P. Mamounas,Norman Wolmark +17 more